Daprodustat

Daprodustat
Clinical data
Trade names	Duvroq, Jesduvroq
Other names	GSK1278863
AHFS/Drugs.com	Monograph
MedlinePlus	a623010
License data	US DailyMed: Daprodustat;
Routes of; administration	By mouth
Drug class	Hypoxia-inducible factor prolyl hydroxylase inhibitor
ATC code	B03XA07 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-[(1,3-dicyclohexyl-2,4,6-trioxo-1,3-diazinane-5-carbonyl)amino]acetic acid;
CAS Number	960539-70-2;
PubChem CID	91617630;
DrugBank	DB11682;
ChemSpider	33427356;
UNII	JVR38ZM64B;
KEGG	D10874;
ChEBI	CHEBI:229223;
ChEMBL	ChEMBL3544988;
CompTox Dashboard (EPA)	DTXSID501337360 ;
ECHA InfoCard	100.219.426
Chemical and physical data
Formula	C19H27N3O6
Molar mass	393.440 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3CCCCC3n(c(=O)c1C(=O)NCC(=O)O)c(=O)n(c1O)C2CCCCC2;
	InChI InChI=1S/C19H27N3O6/c23-14(24)11-20-16(25)15-17(26)21(12-7-3-1-4-8-12)19(28)22(18(15)27)13-9-5-2-6-10-13/h12-13,26H,1-11H2,(H,20,25)(H,23,24); Key:NVTKJBXOBFRPLQ-UHFFFAOYSA-N;

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth.

The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness, and allergic reactions.

Daprodustat was approved for medical use in Japan in June 2020, and in the United States in February 2023. making it the first oral treatment for anemia caused by chronic kidney disease for adults in the US. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.